Patient-reported cognition at the end of a PCSK9 antibody trial - PACE-CME

Patientreported cognition at the end of a PCSK antibody trial

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Reaching LDL-c targets in patients at high CV risk: How well are we doing?
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
MinuteCE®
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
0.75 program credits
- Julia Brandts, MD
0.75 program credits
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
MinuteCE®
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
0.75 program credits
- Pasquale Perrone-Filardi, MD, PhD
0.75 program credits
MinuteCE®
Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA
0.50 credits 3 episodes
- Prof. Alberto Zambon MD, PhD, FAHA
- Prof. Kausik Ray, MBChB, MD, MPhil
- Azfar Zaman, MD
0.50 credits 3 episodes
Understanding the role of triglycerides in the assessment of residual risk
Understanding the role of triglycerides in the assessment of residual risk
MinuteCE®
Understanding the role of triglycerides in the assessment of residual risk
0.50 program credits
- Prof. Alberto Zambon MD, PhD, FAHA
0.50 program credits